Cassava Sciences, Inc. (SAVA)
收市後：
- InvestorPlace
Exit Now! 3 Biotech Stocks to Sell in February 2024
The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges. Moreover, despite forecasts pointing to a potential rebound in 2024, the biotech industry is struggling to adapt post-pandemic. For many biotech firms, securing private funding and launching successful IPOs remains a daunting tas
- Motley Fool
Is There Any Hope for Cassava Sciences Stock?
Battered by controversy, this company will need to show real results to prosper.
- InvestorPlace
3 Biotech Stocks to Sell in January Before They Crash and Burn
The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as companies’ performance relies heavily on drug approvals. A major drug approval has the potential to multiply stock price several times, while a failure to reach approval may cause an immediate, sharp decline. For the following reasons, it is important to choose biotech investments carefully. Below are th
